Grifols Buys Talecris to Increase US Share in Plasma Protein Therapies
Debbie Tranter
Abstract
Grifols SA, European major player in blood plasma products acquires Talecris Biotherapeutics for USD 3 B to expand its share in the US market.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.